ArticleCureus2026
Comparison of the Effectiveness of Greater Occipital Nerve Block and Botulinum Toxin Type A in Chronic Migraine: An Exploratory Pilot Study From a Tertiary Care Centre in a Resource-Limited Setting.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Chronic migraine, defined as ≥15 headache days/month with ≥8 migraine days, is a disabling condition with limited effective treatment options. Greater occipital nerve block (GONB) and botulinum toxin type A (BoNTA) are used in chronic migraine management, yet data from certain regions remain scarce. Objective The objective of this study was to demonstrate the safety and efficacy of GONB and BoNTA treatments in patients with chronic migraine. Methods This prospective, observational, non-blinded exploratory pilot study included 20 adult patients with chronic migraine at a tertiary hospital in India (March 2020-October 2021). Patients were offered either GONB or BoNTA via a cafeteria approach. GONB was administered under ultrasound guidance using lidocaine and methylprednisolone, while BoNTA was injected following the PREEMPT (Phase III REsearch Evaluating Migraine Prophylaxis Therapy) protocol. Headache diaries tracked frequency, severity (via visual analogue scale (VAS)), and medication use for four weeks post intervention. Results Sixteen patients (80%) chose GONB, while four (20%) opted for BoNTA. Mean baseline headache days were 22.63 ± 5.1 (GONB) and 26 ± 4.0 (BoNTA). At four weeks, headache days decreased to 10.81 (GONB) and 12.0 (BoNTA). Mean headache-free days post intervention were 17.19 (GONB) and 15.75 (BoNTA). VAS severity scores improved in both groups, with a marked reduction in high-intensity headache days. No serious adverse events occurred; minor local site pain and transient fatigue were the only reported side effects. Conclusion Both GONB and BoNTA significantly reduced headache frequency and severity in chronic migraine patients with favorable short-term safety profiles. GONB, being more accessible and cost-effective, may offer a viable alternative in resource-limited settings. Both GONB and BoNTA are effective and safe in chronic migraine, with GONB offering a cost-effective, practical option for resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.